Clinical Study on Third-line Treatment of Advanced Duodenal Adenocarcinoma by Fuquinitinib Combined With Sindillimab

Launched by RENJI HOSPITAL · Mar 30, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment approach for patients with advanced duodenal adenocarcinoma, a type of cancer in the intestine that has spread and cannot be surgically removed. The study will analyze the experiences of 20 patients who have received a combination of two medications, furquinelone and sintilimab, as their third line of treatment. This means that these patients have already tried two other treatments that didn’t work for them. The goal is to see how effective and safe this combination of drugs is for managing their cancer.

To be part of this study, patients need to be between 18 and 80 years old and have a confirmed diagnosis of advanced duodenal adenocarcinoma that is no longer treatable with surgery. They should also have a specific level of health status and at least one measurable area of cancer. However, individuals with certain health conditions or those who have had other types of cancer in the last five years won't be eligible to participate. Since this study is still in the planning stages and not yet recruiting participants, there is no specific timeline for when it will begin.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Patients must meet all of the following criteria to be eligible for inclusion:
• • Age between 18 and 80 years (inclusive); Imaging findings consistent with unresectable local advanced, recurrent or metastatic duodenal adenocarcinoma; Histologically confirmed unresectable local advanced, recurrent or metastatic duodenal adenocarcinoma; ECOG performance status 0-2; At least one measurable or evaluable lesion according to RECIST v1.1; Third-line or above treatment with the combination of sintilimab and furquimatinib.
• Exclusion Criteria:
• • -
• Patients meeting any of the following criteria will be excluded:
• • Patients with incomplete clinical data or laboratory examination that affects statistical analysis; Patients who have had other malignant tumors in the past 5 years; Patients who have had arterial thrombotic diseases such as angina, myocardial infarction, and transient ischemic attack in the past 6 months; Patients who have received other types of anti-tumor or experimental treatment; Pregnant or lactating women; Patients with other diseases or abnormal mental status that may affect the patient's treatment; Patients who have received other types of immune therapy, anti-angiogenic drugs, or small-molecule tyrosine kinase inhibitors.